Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Employees - 14, CEO - David A. Happel, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 13.84, Piotroski Score(max is 10): 1, Working Capital: $119949000, Total Assets: $137407000, Retained Earnings: $-323873000, EBIT: -64893000, Total Liabilities: $7247000, Revenue: $0

AryaFin Target Price - $2.41 - Current Price $ - Analyst Target Price $